Italy’s Kedrion Group, a biopharmaceutical company specializing in plasma-derived products, has announced that it will considerably boost capacity at its Hungarian plant, the server Portfolio.hu reported March 19. Ft 5 billion (Kč 480 million) will be spent on Kedrion’s Hungarian plant in Gödöllő, near Budapest, the server said citing local press.
Reportedly, some 60 new jobs will be created at the plant that currently has 140 employees. The upgrade and expansion of the plant is expected to last five years. The Kedrion group also intends to open three new plasmapheresis centers in Germany, the server reported. The Kedrion Group comprises nine companies based in the U.S., Mexico, Switzerland, Germany, Austria and Hungary.